Sabby Capital, founded in 2011, specializes in seed, early-stage, and later-stage investments in the healthcare sector. The firm has a preference for investing in biopharma and therapeutics startups. Sabby Capital has been involved in funding rounds with 7-8 participants, often alongside investors such as Third Rock Ventures, New Enterprise Associates, and Roche Venture Fund. Some of the notable startups in their portfolio include Epic Sciences, Arno Therapeutics, and Stem Cell Therapeutics. The firm tends to invest in companies that have been in operation for 6-10 years and have a single or a small number of founders. Sabby Capital has a strong focus on the United States, both in terms of its own location and its most frequent investments. The firm typically invests in deals ranging from $50 to $100 million and has been particularly active in 2014. Sabby Capital has a higher than average amount of lead investments compared to other organizations and has one valuable employee in its database.